24-Apr-2024
No headlines found.
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
Business Wire (Thu, 11-Apr 8:02 AM ET)
Business Wire (Thu, 11-Apr 8:00 AM ET)
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Business Wire (Wed, 10-Apr 8:00 AM ET)
Business Wire (Tue, 26-Mar 8:00 AM ET)
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
Business Wire (Thu, 15-Feb 1:06 PM ET)
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
Business Wire (Tue, 13-Feb 5:05 PM ET)
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Mei Pharma trades on the NASDAQ stock market under the symbol MEIP.
As of April 24, 2024, MEIP stock price declined to $3.26 with 7,384 million shares trading.
MEIP has a beta of -0.33, meaning it tends to be less sensitive to market movements. MEIP has a correlation of 0.00 to the broad based SPY ETF.
MEIP has a market cap of $21.72 million. This is considered a Sub-Micro Cap stock.
Last quarter Mei Pharma reported $0 in Revenue and -$1.66 earnings per share. This fell short of revenue expectation by $-100,000 and missed earnings estimates by -$.34.
In the last 3 years, MEIP stock traded as high as $78.20 and as low as $3.20.
The top ETF exchange traded funds that MEIP belongs to (by Net Assets): VTI, VXF, IWC, DFAT.
MEIP has underperformed the market in the last year with a price return of +4.2% while the SPY ETF gained +24.2%. MEIP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.0% and -14.7%, respectively, while the SPY returned +4.6% and -2.7%, respectively.
MEIP support price is $3.16 and resistance is $3.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MEIP stock will trade within this expected range on the day.